This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.
This research study is evaluating how patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival) in patient populations with colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy Massachusetts General Hospital Cancer Center
Patient reported outcomes will be collected through a series of self-administered questionnaires and blood draws will be used to obtain bio and tumor marker information. Information will also be collected from the participants electronic medical record. Tissue may be obtained for next-generation sequencing. The study will conclude after participants are no longer receiving anti-cancer therapies. It is expected that about 200 people will take part in this research study
Patients must have histologically confirmed colorectal, pancreatobiliary, or esophagogastric cancer. Diagnosed with metastatic disease Age > 18 years. Patients must be starting new line of anti-cancer therapy. Patient must be English-speaking. Exclusion Criteria Unwilling or unable to participate in the study Non-metastatic disease Not starting new anti-cancer treatment Cognitive issues interfering with ability to participate. Active, unstable, untreated serious mental illness interfering with ability to participate. Patient does not speak English.
